{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T22:07:49Z","timestamp":1778018869497,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Paul K. and Anna M. Shockey Foundation"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain Research Bulletin"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.brainresbull.2013.08.001","type":"journal-article","created":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:15:44Z","timestamp":1377130544000},"page":"122-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Treatment of a relapse-remitting model of multiple sclerosis with opioid growth factor"],"prefix":"10.1016","volume":"98","author":[{"given":"Leslie A.","family":"Hammer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian S.","family":"Zagon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia J.","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.brainresbull.2013.08.001_bib0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/glia.20437","article-title":"Astrogliosis in EAE spinal cord: derivation from radial glia, and relationships to oligodendroglia","volume":"55","author":"Bannerman","year":"2007","journal-title":"Glia"},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0010","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/WNF.0b013e3181880359","article-title":"Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications","volume":"32","author":"Bennett","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0015","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.brainres.2012.07.006","article-title":"Opioid growth factor arrests the progression of clinical disease and spinal cord pathology in established experimental autoimmune encephalomyelitis","volume":"1472","author":"Campbell","year":"2012","journal-title":"Brain Res."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0020","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.brainresbull.2012.09.001","article-title":"Astrocyte proliferation is regulated by the OGF\u2013OGFr axis in vitro and in experimental autoimmune encephalomyelitis","volume":"90","author":"Campbell","year":"2013","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0025","first-page":"R774","article-title":"Internalization of the opioid growth factor, [Met5]-enkephalin, is dependent on clathrin-mediated endocytosis for downregulation of cell proliferation","volume":"299","author":"Cheng","year":"2010","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0030","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1091\/mbc.e08-07-0681","article-title":"The OGF\u2013OGFr axis utilizes the p16INK4a and p21WAF1\/CIP1 pathways to restrict normal cell proliferation","volume":"20","author":"Cheng","year":"2009","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0035","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.intimp.2010.10.005","article-title":"Fingolimod (FTY720), sphingosine-1-phosphate receptor modulator, shows superior efficacy as compared with interferon-\u03b2 in mouse experimental autoimmune encephalomyelitis","volume":"11","author":"Chiba","year":"2011","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0040","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ana.22006","article-title":"Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis","volume":"68","author":"Cree","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0045","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S1474-4422(12)70056-X","article-title":"Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study","volume":"11","author":"Devonshire","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0050","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2174\/157015910792246218","article-title":"Chronic progressive multiple sclerosis\u2014pathogenesis of neurodegeneration and therapeutic strategies","volume":"8","author":"Fitzner","year":"2010","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0055","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1001\/archneur.57.8.1178","article-title":"\u03b2-Endorphin concentrations in peripheral blood mononuclear cells of patients with multiple sclerosis","volume":"57","author":"Gironi","year":"2000","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0060","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1742-2094-9-25","article-title":"Exacerbation of experimental autoimmune encephalomyelitis in prion protein (Pt\/Pc)-null mice evidence for a critical role of the central nervous system","volume":"9","author":"Gourdain","year":"2012","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0065","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.nrl.2010.10.004","article-title":"Natalizumab for relapsing-remitting multiple sclerosis","volume":"26","author":"Horga","year":"2011","journal-title":"Neurologia"},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0070","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/NEN.0b013e3181a41d23","article-title":"Quantification of myelin and axon pathology during relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse","volume":"68","author":"Jackson","year":"2009","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0075","first-page":"433","article-title":"Enkephalins and immune inflammatory reactions","volume":"13","author":"Jankovic","year":"1991","journal-title":"Acta Neurol. (Napoli)"},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0080","doi-asserted-by":"crossref","first-page":"9215","DOI":"10.1523\/JNEUROSCI.20-24-09215.2000","article-title":"Schwann cells are removed from the spinal cord after effecting recovery from paraplegia","volume":"20","author":"Jasmin","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0085","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2249.2009.04050.x","article-title":"Variable effects of cyclophosphamide in rodent models of experimental allergic encephalomyelitis","volume":"159","author":"Mangano","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0090","doi-asserted-by":"crossref","first-page":"8053","DOI":"10.4049\/jimmunol.177.11.8053","article-title":"CSCL12 limits inflammation by localizing mononuclear infiltrates to the perivascular space during experimental autoimmune encephalomyelitis","volume":"177","author":"McCandless","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0095","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.bcp.2012.05.018","article-title":"The opioid growth factor\u2013opioid growth factor receptor axis: homeostatic regulation of cell proliferation and its implications for health and disease","volume":"84","author":"McLaughlin","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0100","doi-asserted-by":"crossref","DOI":"10.1002\/0471142735.im1501s77","article-title":"Experimental autoimmune encephalomyelitis in the mouse","author":"Miller","year":"2007","journal-title":"Curr. Protoc. Immunol."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0105","unstructured":"National Multiple Sclerosis Society, 2013. <http:\/\/www.nationalmssociety.org\/about-the-society\/ms-prevalence\/index.aspx>."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0110","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1084\/jem.20090299","article-title":"Spontaneous relapsing-remitting EAE in the SJL\/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells","volume":"206","author":"Pollinger","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0115","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.brainres.2011.01.036","article-title":"Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: therapeutic implications for multiple sclerosis","volume":"1381","author":"Rahn","year":"2011","journal-title":"Brain Res."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0120","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9","article-title":"The Ki-67 protein: from the known and the unknown","volume":"182","author":"Scholzen","year":"2000","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0125","first-page":"163","article-title":"Cresyl violet staining to assess neuroprotective and neurodegenerative effects of haruan traditional extract against neurodegenerative damage of ketamine","volume":"4","author":"Shafri","year":"2012","journal-title":"Int. J. Pharmacy Pharmaceut. Sci."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0130","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1177\/1352458510366857","article-title":"The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial","volume":"16","author":"Sharafaddinzadeh","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0135","first-page":"22","article-title":"Use of therapies other than disease-modifying agents, including complementary and alternative medicine, by patients with multiple sclerosis: a survey study","volume":"112","author":"Stoll","year":"2012","journal-title":"J. Am. Osteopath. Assoc."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0140","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.4049\/jimmunol.0902881","article-title":"Substrain differences reveal novel disease-modifying gene candidates that alter the clinical course of a rodent model of multiple sclerosis","volume":"184","author":"Summers De Luca","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0145","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/01.jnen.0000229990.32795.0d","article-title":"MMP-12, MMP-3, and TIMP-1 are markedly upregulated in chronic demyelinating Theiler murine encephalomyelitis","volume":"65","author":"Ulrich","year":"2006","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0150","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1742-2094-7-32","article-title":"Chronic upregulation of activated microglia immunoreactive for galectin-3\/Max-2 and nerve growth factor following diffuse axonal injury","volume":"7","author":"Venkatesan","year":"2010","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0155","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jneuroim.2006.06.021","article-title":"Critical role of preproenkephalin in experimental autoimmune encephalomyelitis","volume":"179","author":"Weir","year":"2006","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0160","first-page":"R1154","article-title":"Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers","volume":"297","author":"Zagon","year":"2009","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0165","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.imbio.2010.09.014","article-title":"T lymphocyte proliferation is suppressed by the opioid growth factor ([Met5]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases","volume":"216","author":"Zagon","year":"2011","journal-title":"Immunobiology"},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0170","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.imbio.2010.06.001","article-title":"B lymphocyte proliferation is suppressed by the opioid growth factor\u2013opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases","volume":"216","author":"Zagon","year":"2011","journal-title":"Immunobiology"},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0175","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.brainres.2009.11.026","article-title":"Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis","volume":"1310","author":"Zagon","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0180","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3181\/0906-RM-189","article-title":"Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis","volume":"234","author":"Zagon","year":"2009","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0185","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0165-0173(01)00160-6","article-title":"The biology of the opioid growth factor receptor (OGFr)","volume":"38","author":"Zagon","year":"2002","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0190","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0165-2478(99)00176-5","article-title":"Increased expression of neutral endopeptidase (NEP) and aminopeptidase N (APN) on peripheral blood mononuclear cells in patients with multiple sclerosis","volume":"71","author":"Ziaber","year":"2000","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.brainresbull.2013.08.001_bib0195","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/09629359890857","article-title":"The immunoregulatory abilities of polymorphonuclear neutrophils in the course of multiple sclerosis","volume":"7","author":"Ziaber","year":"1999","journal-title":"Mediators Inflamm."}],"container-title":["Brain Research Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0361923013001354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0361923013001354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T20:18:47Z","timestamp":1759781927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0361923013001354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":39,"alternative-id":["S0361923013001354"],"URL":"https:\/\/doi.org\/10.1016\/j.brainresbull.2013.08.001","relation":{},"ISSN":["0361-9230"],"issn-type":[{"value":"0361-9230","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of a relapse-remitting model of multiple sclerosis with opioid growth factor","name":"articletitle","label":"Article Title"},{"value":"Brain Research Bulletin","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brainresbull.2013.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}